Related references
Note: Only part of the references are listed.Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
Adrian C. Newland et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Efficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia
O. Arbach et al.
TRANSFUSION MEDICINE (2019)
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
James F. Howard et al.
NEUROLOGY (2019)
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
Leona E. Ling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses
L. J. Blumberg et al.
SCIENCE ADVANCES (2019)
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
James Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
FcRn blockade with SYNT001 for the treatment of pemphigus
V. P. Werth et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Emerging Concepts in Immune Thrombocytopenia
Maurice Swinkels et al.
FRONTIERS IN IMMUNOLOGY (2018)
Health-related quality of life in adult primary immune thrombocytopenia
Hanna Gran Sestol et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Results from the ITP World IMPACT Survey (I-WISh): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives
Nichola Cooper et al.
BLOOD (2018)
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Peter Kiessling et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Anne Zufferey et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
Raymond S. M. Wong et al.
BLOOD (2017)
Current Management of Primary Immune Thrombocytopenia
Drew Provan et al.
ADVANCES IN THERAPY (2015)
Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia
Donald M. Arnold et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
Muna Iraqi et al.
HAEMATOLOGICA (2015)
Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange
Atsushi Ohkubo et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2015)
Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
Muna Iraqi et al.
HAEMATOLOGICA (2015)
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
Francesco Rodeghiero et al.
BLOOD (2013)
Therapeutic plasma exchange: A technical and operational review
Andre A. Kaplan
JOURNAL OF CLINICAL APHERESIS (2013)
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
James B. Bussel et al.
BLOOD (2011)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
The ITP syndrome: pathogenic and clinical diversity
Douglas B. Cines et al.
BLOOD (2009)
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
How I treat idiopathic thrombocytopenic purpura (ITP)
DB Cines et al.
BLOOD (2005)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura
R McMillan
SEMINARS IN HEMATOLOGY (2000)
Share Paper
